We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.40 | -1.12% | 35.40 | 35.45 | 36.10 | 36.20 | 35.00 | 35.80 | 241,540 | 16:35:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.66 | 108.86M |
TIDMFUM
RNS Number : 5313E
Futura Medical PLC
18 October 2018
Hot Features
Premium
This announcement has been approved by PrimaryBid Limited (company
number 08092575), which is authorised and regulated by the Financial
Conduct Authority (FRN 779021).
This announcement amounts to a financial promotion for the purposes
of section 21 of the Financial Services and Markets Act 2000,
as amended ("FSMA").
Futura Medical plc
("Futura" or "the Company")
Offer on PrimaryBid.com
At 5.04 p.m. on 18 October 2018 the Company issued an announcement
through an RIS (the "Announcement") of a fundraising (the "Fundraising").
As part of the Fundraising, the Company is delighted to announce
a conditional offer for subscription through PrimaryBid Limited
(the "PrimaryBid Offer"). Completion of the PrimaryBid Offer
is conditional on the fundraising announced by the Company on
18 October 2018 becoming unconditional in all respects.
The PrimaryBid Offer is conditional on, inter alia, the passing
of resolutions at a General Meeting of the Company, which is
expected to be convened for 1.00 p.m. on 12 November 2018.
The PrimaryBid Offer is made on terms which fall within exemptions
from the need to issue a prospectus under the Prospectus Regulation
(Regulation 2003/71/EC) and all subsidiary rules made under
it. Accordingly, the issuance of the PrimaryBid Offer has not
been considered or approved in any way by the Financial Conduct
Authority in its capacity as the UK Listing Authority. The PrimaryBid
Offer is not being made into or from the United States, Canada,
Japan, the Republic of South Africa, Australia, the Republic
of Ireland, New Zealand or any other jurisdiction where to do
so would constitute a violation of the relevant laws or regulations
of that jurisdiction.
Potential investors should make their own investigations into
the merits of an investment in the Company. Nothing in this
announcement amounts to a recommendation to invest in the Company
or amounts to investment, taxation or legal advice. All persons
considering an investment in the Company is recommended to seek
their own professional advice before making any investment.
It should be noted that an application for subscription for
shares in the Company carries a number of risks. Investors should
consider the risk factors set out in the Announcement prior
to making any investment decision in relation to the Company.
PrimaryBid Offer
The Company values its retail investor base and is therefore
pleased to provide private and other investors the opportunity
to participate in the Offer at an issue price of 7p pence per
New Ordinary Share (the "Issue Price"), being a discount of
27.5 per cent to the closing mid-price on 18 October 2018. These
terms are identical to other current and potential investors.
Retail investors can do this through either:
* the www.PrimaryBid.com platform; and
* the PrimaryBid mobile app available on the Apple App
Store and Google Play.
PrimaryBid does not charge investors any commission for the
use of its services.
The PrimaryBid Offer is open to individual and institutional
investors (whether or not existing investors in the Company)
from 5.04 p.m. on 18 October 2018 to no later than 9.00 p.m.
on 18 October 2018. The Offer may close early if it is oversubscribed.
Applications made pursuant to the PrimaryBid Offer will be subject
to the conditions contained in the Fundraising Announcement
and the further conditions of PrimaryBid Limited contained at
https://www.primarybid.com/static/TermsAndConditions.pdf . In
the event of a conflict between the conditions contained in
the Fundraising Announcement and the further conditions of PrimaryBid
Limited, the conditions contained in the Fundraising Announcement
will prevail. In addition, it is to be noted that:
* there is a minimum subscription of GBP100 per
investor under the terms of the Offer which is open
to existing shareholders and other investors
subscribing via PrimaryBid.com;
* the Company and PrimaryBid reserve the right to
reject any application for subscription under the
Offer without giving any reason for such rejection;
and
* any application under the Offer from an Eligible
Counterparty investor will require PrimaryBid to
consult with the Company prior to acceptance of that
application.
For further details please refer to the PrimaryBid.com website
at www.PrimaryBid.com.
The Company may, at its sole discretion, elect to increase the
total number of New Ordinary Shares available under the Offer.
The Company has applied for and received advance assurance from
HMRC that the Ordinary Shares (as defined in the Announcement)
will satisfy the requirements for EIS relief.
The continuing status of the Ordinary Shares as qualifying for
EIS relief will be conditional (amongst other things) on the
qualifying conditions being satisfied, both by the Company and
(as regards those conditions to be met by the investor) the
investor throughout a period of at least three years from the
date of issue. There can be no assurance that the Company will
continue to conduct its activities in a way that will secure
or retain qualifying status for EIS purposes (and indeed circumstances
may arise where the directors of the Company believe that the
interests of the Company are not served by seeking to retain
such status).
There can be no certainty that EIS Advance Assurance will be
reconfirmed.
Investors considering taking advantage of EIS relief are recommended
to seek their own professional advice before investing in order
that they may fully understand how the relief legislation may
apply in their individual circumstances. Any person who is in
any doubt as to his taxation position under the EIS legislation,
or who is subject to tax in a jurisdiction other than the UK,
should consult an appropriate professional adviser.
In relation to VCT relief, persons are advised to consider the
full text of the Announcement.
No commission is charged to investors on applications to participate
in the PrimaryBid Offer.
It is vital to note that once an application for shares as part
of the PrimaryBid Offer has been made and accepted through the
PrimaryBid platform, it cannot be withdrawn (although, as noted
above, the PrimaryBid Offer is conditional and any application
may not be accepted by the Company, for whatever reason).
For further information on the use of the PrimaryBid.com platform
or the procedure for applications under the Offer, visit www.PrimaryBid.com
or call PrimaryBid.com on +44 (0)20 3026 4750.
The Company may, at its sole discretion, elect to increase the
total number of shares available under the PrimaryBid Offer.
All shares issued pursuant to the PrimaryBid Offer will be issued
free of all liens, charges and encumbrances and will, when issued
and fully paid, rank pari passu in all respects with the Company's
existing Ordinary Shares.
A full expected timetable will be made available on the closing
of the Fundraising. An overview of this timetable as applicable
for the PrimaryBid Offer is as follows: Announcement of the PrimaryBid Offer 5.04 p.m. on 18 October
2018
Closing of the PrimaryBid Offer 9.00 p.m. on 18 October
2018
Announcement of the Fundraising by 8.00 a.m. on 19 October
2018
General Meeting 1.00 p.m. on 12 November
2018
Admission and commencement of dealings 8.00 a.m. on 13 November
in shares issued pursuant to the PrimaryBid 2018
Offer on AIM
For further information please contact: +44 (0) 1483 685
Futura Medical plc 670
James Barder, Chief Executive Officer www.futuramedical.com
Angela Hildreth, Finance Director & Chief
Operating Officer
N+1 Singer +44 (0) 207 496 3000
Aubrey Powell / Jen Boorer (Corporate Finance)
Tom Salvesen (Corporate Broking)
PrimaryBid Limited +44 (0) 20 3026 4750
Dave Mutton
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
OFFUWRNRWBARAAA
(END) Dow Jones Newswires
October 18, 2018 12:16 ET (16:16 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
